UNICYCIVE THERAPEUTICS, INC. — Operating Income by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/f99d23ee-8b30-4fdc-bf86-e5b4c31038c7/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-29.5M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-035903 |
| FY 2024 | $-32.1M | 2024-01-01 – 2024-12-31 | evidence 0001213900-25-025828 |
| FY 2023 | $-20.8M | 2023-01-01 – 2023-12-31 | evidence 0001213900-24-027202 |
| FY 2022 | $-18.1M | 2022-01-01 – 2022-12-31 | evidence 0001213900-23-024901 |
| FY 2021 | $-9.0M | 2021-01-01 – 2021-12-31 | evidence 0001213900-22-016384 |
| FY 2020 | $-2.0M | 2020-01-01 – 2020-12-31 | evidence 0001213900-22-016384 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).